ArticleInternational journal of critical illness and injury science
Evaluating the role of high-dose intravenous thiamine supplementation for lactate clearance in patients with cirrhosis and sepsis.
Article in International journal of critical illness and injury science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thiamine is a vitamin that plays a role in lactate clearance. Patients with sepsis may present with elevated lactate, and also in cirrhosis, as lactate is hepatically metabolized. Prior studies showed mixed results regarding the role of thiamine for lactate clearance with limited inclusion of cirrhosis patients. The purpose of this study was to determine the association of high-dose intravenous thiamine on time to lactate clearance among patients with cirrhosis and sepsis. Methods: We performed a single-center retrospective cohort study of critically ill patients with cirrhosis with a diagnosis of sepsis with lactate >4 mmol/L between January 1, 2020, and December 31, 2024. Patients who received ≥400 mg were classified as receiving high-dose thiamine. Fine-Gray competing risks models adjusted for demographic, comorbidity, and illness severity variables estimated the association of receiving high-dose thiamine with time to lactate clearance, defined as a lactate <3 mmol/L. Additional secondary outcomes included intensive care unit and in-hospital mortality. Results: A total of 136 patients were identified and included in the analysis. Median age was 58.4, and 54% were male. Thirty-three patients received high-dose thiamine. Patients had similar baseline characteristics, including on indicators of illness severity, cirrhosis severity, and use of vasopressors. In both unadjusted and adjusted models, the receipt of high-dose thiamine was not associated with differences in time to lactate clearance or mortality. Conclusions: Thiamine use in patients with cirrhosis who experienced sepsis did not result in improved lactate clearance compared to those who did not receive high-dose thiamine. These data do not support empiric high-dose thiamine to aid lactate clearance in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.